Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

aTYR PHARMA (ATYR) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for aTYR PHARMA (ATYR) over the last 7 years, with Q3 2025 value amounting to $18000.0.

  • aTYR PHARMA's Change in Accured Expenses fell 9919.75% to $18000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year increase of 849.67%. This contributed to the annual value of -$1.3 million for FY2024, which is 14104.84% down from last year.
  • aTYR PHARMA's Change in Accured Expenses amounted to $18000.0 in Q3 2025, which was down 9919.75% from $4.8 million recorded in Q2 2025.
  • Over the past 5 years, aTYR PHARMA's Change in Accured Expenses peaked at $4.8 million during Q2 2025, and registered a low of -$4.3 million during Q1 2025.
  • In the last 5 years, aTYR PHARMA's Change in Accured Expenses had a median value of $216000.0 in 2022 and averaged $484947.4.
  • Per our database at Business Quant, aTYR PHARMA's Change in Accured Expenses soared by 93500.0% in 2022 and then crashed by 1109736.84% in 2024.
  • Quarter analysis of 5 years shows aTYR PHARMA's Change in Accured Expenses stood at $180000.0 in 2021, then skyrocketed by 935.0% to $1.9 million in 2022, then skyrocketed by 81.86% to $3.4 million in 2023, then tumbled by 75.65% to $825000.0 in 2024, then crashed by 97.82% to $18000.0 in 2025.
  • Its last three reported values are $18000.0 in Q3 2025, $4.8 million for Q2 2025, and -$4.3 million during Q1 2025.